ObjectiveGI, the integrated research and technology services platform company, announced its 10th “Center of Research Excellence.” ObjectiveGI is a physician-partnered model that integrates gastroenterology (GI) research services into local practices, providing clinical research as a management option for specialists in support of patient care and practice enhancement. With this 10th center, the company is now partnering with more than 100 GI physicians across the country.
“It’s an exciting time to be in healthcare and support science at the point of care,” says Colleen Hoke, president and CEO, ObjectiveGI. “By partnering with leading GI physicians to create cutting-edge programs, we’re working together to provide the necessary data aimed at developing new NASH therapies and, ultimately, improving patient outcomes.”
Since launching the first “Center of Research Excellence” in 2018, ObjectiveGI and its partners have supported value-based care initiatives for more than 3,000 patients. Today, these centers can be found on-site at GI practices located in Alabama, Arkansas, Florida, Maryland, Michigan, North Carolina, South Carolina and Tennessee. Looking forward, ObjectiveGI plans to double the number of “Center of Excellence” sites by the end of 2020, expanding its transformative presence while driving meaningful partnerships and improved patient outcomes.
“We will continue to add value for all stakeholders and advance emerging care solutions for patients through each one of our research partnerships,” says Dr. Don Lazas, chief medical officer, ObjectiveGI. “Aligning incentives for research sponsors and payers, while providing a premier research infrastructure that allows for GI providers to conduct pivotal clinical trials within the workflow of their practices, remains at the forefront of the work with our physician partners.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.